Laurus Labs Ltd

Laurus Labs Ltd

₹ 400 1.14%
27 Feb 3:48 p.m.
About

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership
position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing.
Laurus employs 6500+ people, including around 1050+ scientists at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Key Points

Integrated Pharma Company[1] Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in Active Pharmaceutical Ingredients (APIs) in selected high-growth therapeutic areas and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.

  • Market Cap 21,556 Cr.
  • Current Price 400
  • High / Low 445 / 279
  • Stock P/E 105
  • Book Value 75.2
  • Dividend Yield 0.51 %
  • ROCE 22.2 %
  • ROE 20.4 %
  • Face Value 2.00

Pros

  • Company has delivered good profit growth of 34.4% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 27.3%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,272 1,399 1,221 1,176 933 1,378 1,495 1,498 1,501 1,279 1,108 1,158 1,132
858 936 858 842 717 1,005 1,077 1,072 1,116 1,027 980 978 962
Operating Profit 415 462 363 334 215 373 418 426 385 252 128 181 170
OPM % 33% 33% 30% 28% 23% 27% 28% 28% 26% 20% 12% 16% 15%
9 6 8 4 7 2 3 4 3 6 7 6 11
Interest 17 21 25 21 21 29 28 38 39 41 33 38 38
Depreciation 49 51 55 59 60 61 66 76 78 81 84 85 87
Profit before tax 357 396 290 258 142 285 328 317 270 137 17 63 57
Tax % 25% 26% 23% 24% 23% 22% 29% 28% 26% 25% 24% 26% 25%
267 293 222 198 109 221 232 227 199 102 13 47 43
EPS in Rs 4.98 5.46 4.14 3.68 2.03 4.12 4.31 4.23 3.70 1.90 0.24 0.87 0.79
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
451 719 1,160 1,326 1,775 1,892 2,027 2,236 2,797 4,769 4,707 5,773 4,677
373 573 951 1,121 1,402 1,478 1,618 1,884 2,226 3,258 3,421 4,292 3,946
Operating Profit 78 145 209 205 372 414 409 352 571 1,511 1,286 1,482 731
OPM % 17% 20% 18% 15% 21% 22% 20% 16% 20% 32% 27% 26% 16%
1 5 9 34 4 32 28 15 5 26 20 16 29
Interest 40 41 64 106 111 97 75 86 88 66 96 146 150
Depreciation 18 23 33 61 86 104 121 161 184 197 235 301 337
Profit before tax 22 86 121 72 180 245 241 121 304 1,275 975 1,051 274
Tax % 0% -2% 20% -2% 19% 18% 28% 22% 12% 25% 23% 28%
22 88 97 74 145 200 173 95 267 956 750 760 205
EPS in Rs 2.83 11.58 12.64 9.47 18.36 3.78 3.27 1.78 5.00 17.82 13.96 14.12 3.80
Dividend Payout % 0% 0% 0% 0% 2% 8% 9% 17% 10% 11% 14% 14%
Compounded Sales Growth
10 Years: 23%
5 Years: 23%
3 Years: 27%
TTM: -20%
Compounded Profit Growth
10 Years: 24%
5 Years: 34%
3 Years: 42%
TTM: -77%
Stock Price CAGR
10 Years: %
5 Years: 43%
3 Years: 4%
1 Year: 25%
Return on Equity
10 Years: 22%
5 Years: 23%
3 Years: 27%
Last Year: 20%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 15 15 15 16 16 106 106 106 107 107 107 108 108
Reserves 91 182 281 645 790 1,250 1,407 1,484 1,709 2,605 3,281 3,949 3,945
Preference Capital 62 62 62 67 67 0 0 0 0 0 0 0
225 292 543 821 1,015 808 947 1,009 1,051 1,411 1,653 1,714 1,808
181 212 434 411 409 509 547 718 872 1,502 1,567 1,187 1,461
Total Liabilities 513 701 1,273 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,322
187 236 499 801 1,014 1,193 1,448 1,599 1,694 1,818 2,186 2,884 3,001
CWIP 32 73 116 107 70 143 163 107 67 324 755 357 231
Investments 0 0 0 19 26 51 52 58 58 319 362 384 432
294 393 658 966 1,119 1,286 1,345 1,554 1,920 3,164 3,306 3,333 3,657
Total Assets 513 701 1,273 1,893 2,229 2,673 3,008 3,318 3,739 5,625 6,609 6,958 7,322

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
39 88 121 -59 197 321 369 293 345 694 823 882
-46 -124 -312 -406 -315 -282 -417 -257 -217 -900 -837 -735
11 34 203 486 90 -47 49 -37 -127 243 15 -185
Net Cash Flow 4 -2 12 21 -27 -8 0 -0 0 38 2 -39

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 120 80 61 78 91 108 100 112 102 98 98 94
Inventory Days 136 138 165 210 177 184 199 201 233 257 279 211
Days Payable 133 117 114 101 91 110 106 144 157 194 140 90
Cash Conversion Cycle 123 101 112 187 177 183 193 169 177 161 237 216
Working Capital Days 120 93 48 119 117 126 124 116 119 127 140 138
ROCE % 17% 27% 25% 15% 17% 17% 14% 8% 14% 38% 23% 22%

Shareholding Pattern

Numbers in percentages

Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
27.45% 27.30% 27.30% 27.27% 27.27% 27.27% 27.27% 27.20% 27.20% 27.20% 27.20% 27.18%
20.68% 21.54% 22.82% 22.08% 22.45% 21.98% 22.67% 21.90% 22.42% 22.52% 24.03% 25.39%
3.56% 4.15% 4.81% 6.90% 7.93% 9.11% 9.34% 9.51% 9.74% 10.36% 11.01% 11.13%
48.31% 47.01% 45.06% 43.76% 42.36% 41.65% 40.74% 41.38% 40.64% 39.93% 37.75% 36.30%
No. of Shareholders 2,35,8362,99,2573,94,0534,67,4194,27,4654,07,1863,90,6954,23,9314,18,6154,17,9774,02,6403,82,880

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls